

Table S1: *C. albicans* strains used in this study

Strain	Parent	Description/Relevant genotype	Reference
SC5314		wild-type reference strain	(4)
F2		fluconazole-sensitive isolate	(2)
F5		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(2)
G2		fluconazole-sensitive isolate	(2)
G5		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(2)
B3		fluconazole-sensitive isolate	(3)
B4		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(3)
DSY291 (C37) ¹		fluconazole-sensitive isolate	(9)
DSY292 (C40) ¹		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(9)
DSY2285 (26) ¹		fluconazole-sensitive isolate	(1)
DSY2286 (91) ¹		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(1)
1442		fluconazole-sensitive isolate	(5)
2271		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(5)
1490		fluconazole-sensitive isolate	(5)
1587		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(5)
5044		fluconazole-sensitive isolate	(7)
5052		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(7)
5833		fluconazole-sensitive isolate	(8)
6692		fluconazole-resistant isolate, <i>MDR1</i> overexpression	(8)
SCMRR1R34A and -B	SC5314	<i>MRR1</i> ^{P683S} - <i>FRT</i> / <i>MRR1</i> ^{P683S} - <i>FRT</i>	(10)
SCCAP1R14A and -B	SC5314	<i>CAP1</i> ^{ΔC333} - <i>FRT</i> / <i>CAP1</i> ^{ΔC333} - <i>FRT</i>	(10)
SCMPG2A and -B	SC5314	<i>ACT1/act1::P_{MDR1-2}-GFP-caSAT1</i>	(6)
SCMPG2S2A and -B	SC5314	<i>ACT1/act1::P_{MDR1-1}-GFP-caSAT1</i>	this study
SCMRR1R34MPG2A	SCMRR1R34A	<i>MRR1</i> ^{P683S} - <i>FRT</i> / <i>MRR1</i> ^{P683S} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-2}-GFP-caSAT1</i>	(10)
SCMRR1R34MPG2B	SCMRR1R34B	<i>MRR1</i> ^{P683S} - <i>FRT</i> / <i>MRR1</i> ^{P683S} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-2}-GFP-caSAT1</i>	(10)
SCMRR1R34MPG2S2A	SCMRR1R34A	<i>MRR1</i> ^{P683S} - <i>FRT</i> / <i>MRR1</i> ^{P683S} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-1}-GFP-caSAT1</i>	this study
SCMRR1R34MPG2S2B	SCMRR1R34B	<i>MRR1</i> ^{P683S} - <i>FRT</i> / <i>MRR1</i> ^{P683S} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-1}-GFP-caSAT1</i>	this study
SCCAP1R14MPG2A	SCCAP1R14A	<i>CAP1</i> ^{ΔC333} - <i>FRT</i> / <i>CAP1</i> ^{ΔC333} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-2}-GFP-caSAT1</i>	(10)
SCCAP1R14MPG2B	SCCAP1R14B	<i>CAP1</i> ^{ΔC333} - <i>FRT</i> / <i>CAP1</i> ^{ΔC333} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-2}-GFP-caSAT1</i>	(10)
SCCAP1R14MPG2S2A	SCCAP1R14A	<i>CAP1</i> ^{ΔC333} - <i>FRT</i> / <i>CAP1</i> ^{ΔC333} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-1}-GFP-caSAT1</i>	this study
SCCAP1R14MPG2S2B	SCCAP1R14B	<i>CAP1</i> ^{ΔC333} - <i>FRT</i> / <i>CAP1</i> ^{ΔC333} - <i>FRT</i> <i>ACT1/act1::P_{MDR1-1}-GFP-caSAT1</i>	this study

¹ Names in parentheses are previously used strain designations.

References

1. **Calabrese, D., J. Bille, and D. Sanglard.** 2000. A novel multidrug efflux transporter gene of the major facilitator superfamily from *Candida albicans* (*FLU1*) conferring resistance to fluconazole. *Microbiology* **146**:2743-54.
2. **Franz, R., S. L. Kelly, D. C. Lamb, D. E. Kelly, M. Ruhnke, and J. Morschhäuser.** 1998. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical *Candida albicans* strains. *Antimicrob Agents Chemother* **42**:3065-72.
3. **Franz, R., M. Ruhnke, and J. Morschhäuser.** 1999. Molecular aspects of fluconazole resistance development in *Candida albicans*. *Mycoses* **42**:453-8.
4. **Gillum, A. M., E. Y. Tsay, and D. R. Kirsch.** 1984. Isolation of the *Candida albicans* gene for orotidine-5'-phosphate decarboxylase by complementation of *S. cerevisiae* *ura3* and *E. coli* *pyrF* mutations. *Mol Gen Genet* **198**:179-82.
5. **Lopez-Ribot, J. L., R. K. McAtee, L. N. Lee, W. R. Kirkpatrick, T. C. White, D. Sanglard, and T. F. Patterson.** 1998. Distinct patterns of gene expression associated with development of fluconazole resistance in serial *Candida albicans* isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis. *Antimicrob Agents Chemother* **42**:2932-7.
6. **Morschhäuser, J., K. S. Barker, T. T. Liu, J. Blaß-Warmuth, R. Homayouni, and P. D. Rogers.** 2007. The transcription factor Mrr1p controls expression of the *MDR1* efflux pump and mediates multidrug resistance in *Candida albicans*. *PLoS Pathog* **3**:e164.
7. **Perea, S., J. L. Lopez-Ribot, W. R. Kirkpatrick, R. K. McAtee, R. A. Santillan, M. Martinez, D. Calabrese, D. Sanglard, and T. F. Patterson.** 2001. Prevalence of Molecular Mechanisms of Resistance to Azole Antifungal Agents in *Candida albicans* Strains Displaying High-Level Fluconazole Resistance Isolated from Human Immunodeficiency Virus-Infected Patients. *Antimicrob Agents Chemother* **45**:2676-84.
8. **Saidane, S., S. Weber, X. De Deken, G. St-Germain, and M. Raymond.** 2006. *PDR16*-mediated azole resistance in *Candida albicans*. *Mol Microbiol* **60**:1546-62.
9. **Sanglard, D., K. Kuchler, F. Ischer, J. L. Pagani, M. Monod, and J. Bille.** 1995. Mechanisms of resistance to azole antifungal agents in *Candida albicans* isolates from AIDS patients involve specific multidrug transporters. *Antimicrob Agents Chemother* **39**:2378-86.
10. **Schubert, S., K. S. Barker, S. Znaidi, S. Schneider, F. Dierolf, N. Dunkel, M. Aid, G. Boucher, P. D. Rogers, M. Raymond, and J. Morschhäuser.** 2011. Regulation of efflux pump expression and drug resistance by the transcription factors Mrr1, Upc2, and Cap1 in *Candida albicans*. *Antimicrob Agents Chemother* **55**:2212-23.